안진희 교수
#유방암#골연부조직육종
|
학력
2001 .03 ~ 2003 .02울산대학교 의학 박사
1999 .03 ~ 2001 .02울산대학교 의학 석사
1989 .03 ~ 1995 .02한양대학교 의학 학사
1999 .03 ~ 2001 .02울산대학교 의학 석사
1989 .03 ~ 1995 .02한양대학교 의학 학사
경력
2016 .04 ~ 현재울산대학교 의과대학 서울아산병원 종양내과 교수
2012 .03 ~ 2013 .02Harvard Medical School, Dana-Faber Cancer Institute 방문연구원
2010 .04 ~ 2016 .03울산대학교 의과대학 서울아산병원 종양내과 부교수
2005 .03 ~ 2010 .03울산대학교 의과대학 서울아산병원 종양내과 조교수
2003 .03 ~ 2005 .02서울아산병원 임상전임강사
2000 .03 ~ 2003 .02서울아산병원 전임의
1996 .03 ~ 2000 .02서울아산병원 전공의
1995 .03 ~ 1996 .02서울아산병원 인턴
2012 .03 ~ 2013 .02Harvard Medical School, Dana-Faber Cancer Institute 방문연구원
2010 .04 ~ 2016 .03울산대학교 의과대학 서울아산병원 종양내과 부교수
2005 .03 ~ 2010 .03울산대학교 의과대학 서울아산병원 종양내과 조교수
2003 .03 ~ 2005 .02서울아산병원 임상전임강사
2000 .03 ~ 2003 .02서울아산병원 전임의
1996 .03 ~ 2000 .02서울아산병원 전공의
1995 .03 ~ 1996 .02서울아산병원 인턴
논문
Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study.
Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive
A Randomized Feasibility Study of (18)F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer.
Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer.
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline.
A randomized feasibility study of 18F-fluoroestradiol positron emission tomography to predict pathological response to neoadjuvant systemic therapy in estrogen receptor-rich postmenopausal breast cancer.
Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in breast cancer.
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Monogenic and polygenic determinants of sarcoma risk: an international genetic study.
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change aft
Postoperative Radiotherapy After Limb-sparing Surgery for Soft-tissue Sarcomas of the Distal Extremities.
A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer.
Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer.
Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab
Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers
High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers
Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.
Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Pulmonary Metastasectomy Could Prolong Overall Survival in Select Cases of Metastatic Urinary Tract Cancer.
RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.
Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-na?ve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenoca
Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer
Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
Active surveillance for metastatic or recurrent renal cell carcinoma.
Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial
Correlations between molecular subtypes and pathologic response patterns of breast cancers after neoadjuvant chemotherapy.
Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients
Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive
A Randomized Feasibility Study of (18)F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer.
Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer.
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline.
A randomized feasibility study of 18F-fluoroestradiol positron emission tomography to predict pathological response to neoadjuvant systemic therapy in estrogen receptor-rich postmenopausal breast cancer.
Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in breast cancer.
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Monogenic and polygenic determinants of sarcoma risk: an international genetic study.
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change aft
Postoperative Radiotherapy After Limb-sparing Surgery for Soft-tissue Sarcomas of the Distal Extremities.
A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer.
Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer.
Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab
Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers
High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers
Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.
Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Pulmonary Metastasectomy Could Prolong Overall Survival in Select Cases of Metastatic Urinary Tract Cancer.
RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.
Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-na?ve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenoca
Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer
Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
Active surveillance for metastatic or recurrent renal cell carcinoma.
Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial
Correlations between molecular subtypes and pathologic response patterns of breast cancers after neoadjuvant chemotherapy.
Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients
저서
유방암 환자를 위한 치료 안내서 5판
암에 대한 모든 것 (가림건강신서 54)
암에 대한 모든 것 (가림건강신서 54)
보도자료
포스팅
FcrR3A-158 polymorphism and stromal tumor-infiltrating lymphocytes as predictive markers for trastuzumab-based treatment in patients with metastatic HER2-positive breast cancer
Treatment and Prognosis of Desmoid Tumor: A Single Institutional Experience of 189 Patients
Differential Expression of Major Histocompatibility Complex I in Subtypes of Breast Cancer
Differential Expression of Major Histocompatibility Complex I in Subtypes of Breast Cancer
Improvement Activities Linked with Customer Journey Map of Breast Cancer Patients
RandomizEd phase II trial of Sunitinib four-week on and two-week off vs.Two-week On and one-week off in metastatic clear cell type REnal cell carcinoma: RESTORE trial (NCT00570882)
Activity of gemcitabine-oxaliplatin (GemOx) plus prednisolone in patients with castration-resistant prostate cancer (CRPC) for whom docetaxel-based chemotherapy failed
Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI) is Active in Patients with Metastatic Renal Cell Carcinoma (mRCC) with Poor Risk Features
Comparative Efficacy of Sunitinib versus Sorafenib as First-line Treatment for Patients with Metastatic Renal Cell Carcinoma
Clinical features and outcomes of leptomeningeal metastasis in patients with breast cancer: a single center experience
Gamma Knife Surgery (GKS) Alone versus GKS Followed by Whole Brain Radiotherapy (WBRT) as the Initial Treatment of Brain Metastasis
Clinicopathologic significance of the triple negative breast cancer associated with basal phenotype : a comparison with status of androgen receptor expression
Does the primary lesion have to be regarded as a target lesion when evaluating response in metastatic renal cell carcinoma (mRCC) treated with sunitinib?
Clinical characteristics, survival and prognostic factors of advanced renal cell carcinoma with predominant sarcomatoid histology
Treatment and Prognosis of Desmoid Tumor: A Single Institutional Experience of 189 Patients
Differential Expression of Major Histocompatibility Complex I in Subtypes of Breast Cancer
Differential Expression of Major Histocompatibility Complex I in Subtypes of Breast Cancer
Improvement Activities Linked with Customer Journey Map of Breast Cancer Patients
RandomizEd phase II trial of Sunitinib four-week on and two-week off vs.Two-week On and one-week off in metastatic clear cell type REnal cell carcinoma: RESTORE trial (NCT00570882)
Activity of gemcitabine-oxaliplatin (GemOx) plus prednisolone in patients with castration-resistant prostate cancer (CRPC) for whom docetaxel-based chemotherapy failed
Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI) is Active in Patients with Metastatic Renal Cell Carcinoma (mRCC) with Poor Risk Features
Comparative Efficacy of Sunitinib versus Sorafenib as First-line Treatment for Patients with Metastatic Renal Cell Carcinoma
Clinical features and outcomes of leptomeningeal metastasis in patients with breast cancer: a single center experience
Gamma Knife Surgery (GKS) Alone versus GKS Followed by Whole Brain Radiotherapy (WBRT) as the Initial Treatment of Brain Metastasis
Clinicopathologic significance of the triple negative breast cancer associated with basal phenotype : a comparison with status of androgen receptor expression
Does the primary lesion have to be regarded as a target lesion when evaluating response in metastatic renal cell carcinoma (mRCC) treated with sunitinib?
Clinical characteristics, survival and prognostic factors of advanced renal cell carcinoma with predominant sarcomatoid histology
영상자료
영상자료 내용이 없습니다.
발표자료
Hepatitis B Reactivation During Adjuvant Anthracycline Based Chemotherapy in Patients with Breast Cancer : Single Institution Experience
Prognostic Significance of Stem cell Property in Breast Carcinoma: Immunohistochemical Study for CD44s and CD24
18F-FDG PET Scan as a Predictor of Survival of the Patients Receiving Neoadjuvant Chemoradiotherapy Followed by Esophagectomy
Efficacy of gemcitabine alone and in combination with vinorelbine or capecitabine in metastatic breast cancer settings of disease progression after anthracycline and taxane therapy
Multivariate Prognostic Factor Analysis in Patients with Esophageal Cancer Treated with Preoperative Chemoradiotherapy (CRT): The Importance of Pathologic Response and Lymph Node Metastasis
Gemcitabine single or combination chemotherapy in post anthracycline and taxane salvage treatment of metastatic breast cancer: Retrospective analysis of 124 patients
Hepatitis B Reactivation During Adjuvant Anthracycline Based Chemotherapy in Patients with Breast Cancer : Single Institution Experience
Multivariate prognostic factor analysis in patients with esophageal cancer treated with preoperative chemoradiation: the importance of pathologic response and lymph node metastasis
Incidence of chemotherapy-related amenorrhea and menopause-specific quality of life after adjuvant therapy in premenopausal breast cancer patients: A prospective study
Cytokeratin Expression Profiling in the Matrix-Producing Metaplastic Carcinoma of Breast
BRCA1/2 Associated Korean Breast Cancer has more often ER/C-ERBB2 negative phenotype
Bone mineral density and the risk of breast cancer
Clinicopathologic Significance of a-Basic Crystallin in Breast Cancer
Prognostic Significance of Stem Cell Property in Breast Carcinoma: Iuumonhistochemical Study for CD44s and CD24
Predictor of locoregional recurrence to plan breast conservation therapy for breast cancer
Comparison between surgical and non-surgical treatment for tonsillar squamous cell carcinoma
Prognostic Significance of Stem cell Property in Breast Carcinoma: Immunohistochemical Study for CD44s and CD24
18F-FDG PET Scan as a Predictor of Survival of the Patients Receiving Neoadjuvant Chemoradiotherapy Followed by Esophagectomy
Efficacy of gemcitabine alone and in combination with vinorelbine or capecitabine in metastatic breast cancer settings of disease progression after anthracycline and taxane therapy
Multivariate Prognostic Factor Analysis in Patients with Esophageal Cancer Treated with Preoperative Chemoradiotherapy (CRT): The Importance of Pathologic Response and Lymph Node Metastasis
Gemcitabine single or combination chemotherapy in post anthracycline and taxane salvage treatment of metastatic breast cancer: Retrospective analysis of 124 patients
Hepatitis B Reactivation During Adjuvant Anthracycline Based Chemotherapy in Patients with Breast Cancer : Single Institution Experience
Multivariate prognostic factor analysis in patients with esophageal cancer treated with preoperative chemoradiation: the importance of pathologic response and lymph node metastasis
Incidence of chemotherapy-related amenorrhea and menopause-specific quality of life after adjuvant therapy in premenopausal breast cancer patients: A prospective study
Cytokeratin Expression Profiling in the Matrix-Producing Metaplastic Carcinoma of Breast
BRCA1/2 Associated Korean Breast Cancer has more often ER/C-ERBB2 negative phenotype
Bone mineral density and the risk of breast cancer
Clinicopathologic Significance of a-Basic Crystallin in Breast Cancer
Prognostic Significance of Stem Cell Property in Breast Carcinoma: Iuumonhistochemical Study for CD44s and CD24
Predictor of locoregional recurrence to plan breast conservation therapy for breast cancer
Comparison between surgical and non-surgical treatment for tonsillar squamous cell carcinoma